UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

             CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                       (Date of earliest event reported):

                                 April 20, 2004



                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)


        DELAWARE                         000-29089               06-1562417

(State or other jurisdiction of   (Commission file number)  (I.R.S. Employer
 incorporation of organization)                              Identification No.)

                          630 FIFTH AVENUE, SUITE 2100
                            NEW YORK, NEW YORK 10111
              (Address of principal executive offices and zip code)

                                 (212) 994-8200
              (Registrant's telephone number, including area code)










Item 7.   Financial Statements, Pro Forma Financial Statements and Exhibits.

(c) Exhibits:

99.1   Press Release dated April 20, 2004

Item 12.  Disclosure of Results of Operations and Financial Condition

          On April 20, 2004, Antigenics Inc. announced its financial results for
          the quarter ended March 31, 2004. The full text of the press release
          issued in connection with the announcement is attached as Exhibit 99.1
          to this current report on Form 8-K.

          The information in this report on Form 8-K and the Exhibit attached
          hereto is being furnished pursuant to Item 12 of Form 8-K, Disclosure
          of Results of Operations and Financial Condition. The information
          shall not be deemed "filed" for purposes of Section 18 of the
          Securities Exchange Act of 1934 (the "Exchange Act") or otherwise
          subject to the liabilities of that section, nor shall it be deemed
          incorporated by reference in any filing under the Securities Act of
          1933 or the Exchange Act, except as expressly set forth by specific
          reference in such a filing.








                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                              ANTIGENICS INC.

Date: April 20, 2004
                                                     By:    /s/ Garo H. Armen
                                                         --------------------

                                                         Garo H. Armen, Ph.D.
                                         Chairman and Chief Executive Officer







                                  EXHIBIT INDEX


The following designated exhibits are filed herewith:

Exhibits:

99.1     Press Release dated April 20, 2004